SCHEMBL3522935

SCHEMBL3522935

COc1ccc(F)c(F)c1C(=O)c1cnc(Nc2ccc(S(N)(=O)=O)cc2)nc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 10/20 0.59
CDK1 P06493 9/20 0.59
CDK4 P11802 7/20 0.59
CCND1 P24385 7/20 0.59
CDK9 P50750 4/20 0.59
CDK5 Q00535 3/20 0.59
GSK3A P49840 3/20 0.59
GSK3B P49841 3/20 0.59
EGFR P00533 2/20 0.59
ROCK2 O75116 2/20 0.59
STK10 O94804 2/20 0.59
CDK14 O94921 2/20 0.59
ABL1 P00519 2/20 0.59
CDK11B P21127 2/20 0.59
TTK P33981 2/20 0.59
CLK1 P49759 2/20 0.59
CLK2 P49760 2/20 0.59
CLK3 P49761 2/20 0.59
CDK7 P50613 2/20 0.59
CDK3 Q00526 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521339 0.93 CDK1 (0.61) CDK2CDK1CDK4CCND1CDK9
SCHEMBL3519627 0.90 CDK2 (0.50) CDK2CDK1CDK4CCND1CDK9
SCHEMBL3522264 0.83 CDK1 (0.52) CDK2CDK1CDK4CCND1CDK9
SCHEMBL3522463 0.77 CDK1 (0.89) CDK2CDK1CDK4CCND1CDK9
SCHEMBL5393063 0.76 CDK1 (0.80) CDK2CDK1CDK4CCND1CDK9
SCHEMBL3520853 0.76 CDK1 (0.80) CDK2CDK1CDK4CCND1CDK9
SCHEMBL4348141 0.76 CDK1 (0.84) CDK2CDK1CDK4CCND1CDK9
SCHEMBL4350088 0.76 CDK1 (0.55) CDK2CDK1CDK4CCND1CDK9
SCHEMBL4357274 0.76 CDK1 (0.71) CDK2CDK1CDK4CCND1CDK9
SCHEMBL4351750 0.76 CDK1 (0.76) CDK2CDK1CDK4CCND1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705009-B2 4-aminopyrimidine-5-thione derivatives HOFFMAN-LA ROCHE INC. (US) 2010-04-27 US disclosed
US-7705009-B2 4-aminopyrimidine-5-thione derivatives HOFFMAN-LA ROCHE INC. (US) 2010-04-27 US disclosed
US-7705009-B2 4-aminopyrimidine-5-thione derivatives HOFFMAN-LA ROCHE INC. (US) 2010-04-27 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
EP-1957466-A1 4-AMINOPYRIMIDINE-5-THIONE-DERIVATIVES FOR THE TREATMENT OF CANCER F.HOFFMANN-LA ROCHE AG (CH) 2008-08-20 EP disclosed
WO-2007060110-A1 4-AMINOPYRIMIDINE-5-THIONE-DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-05-31 WO disclosed
WO-2007060110-A1 4-AMINOPYRIMIDINE-5-THIONE-DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-05-31 WO disclosed
US-20070117821-A1 4-Aminopyrimidine-5-thione derivatives DING QINGJIE 2007-05-24 US disclosed
US-20070117821-A1 4-Aminopyrimidine-5-thione derivatives DING QINGJIE 2007-05-24 US disclosed
US-20070117821-A1 4-Aminopyrimidine-5-thione derivatives DING QINGJIE 2007-05-24 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK2 4/4885CDK1 6/4885CDK4 1/4885
US-20070117821-A1 4-Aminopyrimidine-5-thione derivatives CDK4, CDK1, CDK2 CDK2 3/4885CDK1 2/4885CDK4 1/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK2 3/4885CDK1 6/4885CDK4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.